This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Oxford spin out partners with J&J to transform lung cancer treatment

Optellum, a lung health start-up in Oxford, aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software.

Optellum, a lung-health AI company in Oxford has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson. Through the collaboration, Optellum will apply its AI-powered clinical decision support platform with the goal of increasing lung cancer survival rates through early intervention and prevention.

Optellum was co-founded by Oxford cancer researcher Prof. Sir Michael Brady (Department of Oncology) with the mission of seeing every lung disease patient diagnosed and treated at the earliest possible stage, and cured.

Read the full story on the Oxford Cancer website.

Optellum featured as our first case study here